Despite being the subject of several independent studies, the relationship between Interleukine-6 (IL-6) polymorphisms and kidney graft outcome continue to be plagued by contradictory conclusions. In this meta-analysis we collect all the relevant studies to further clarify the association of IL-6 genotypes and Chronic Nephropathy of the Graft (CNG). Relevant published data was retrieved through Medline with references to kidney transplant outcome and IL-6 polymorphisms. Odds ratios (OR) with 95% confidence intervals (CI) were used to assess the strength of the association. Z test was used to determine the significance of the pooled OR. Statistical heterogeneity was measured using the Q statistic. A total of 6 studies, including 474 transplanted patients with CNG and 731 transplanted patients as control group with stable graft function, were collected. The distribution of IL-6 polymorphims was evaluated and no heterogeneity was observed among individual estimates. Original data was combined using the fixed-effects model. For the total population, we found that G/G and G/C IL-6 genotypes were less common in the CNG group than in the control group with an OR of 0.61, (95 % CI = 0.42-0.87), and p = 0.006, which shows a protective association of IL-6 high producers genotypes in the CNG group. IL-6 is both a major proinflammatory cytokine and an important anti-inflammatory mediator, these complex actions would yield variable effects on atherosclerosis and cardiovascular risk profile in kidney transplant recipients. Our comprehensive meta-analysis indicated that there is sufficient evidence to demonstrate an association between the IL-6 polymorphisms and CNG after kidney transplantation.
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INTERLEUKINE-6 PROMOTER POLYMORPHISM -174G/C IS NOT ASSOCIATED WITH ACUTE REJECTION EPISODES AFTER KIDNEY TRANSPLANTATION: A META-ANALYSIS Bruno Lima 1 , Miguel Mendes 1 , Helena Alves 2
Proinflammatory and anti-inflammatory cytokines play key roles in immunologic phenomena leading to Acute Rejection Episodes (ARE) after kidney transplantation which are responsible for kidney graft loss. In particular, interleukin-6 (IL-6), regulates the immune response by acting on various cells including differentiation and maturation of B and T cells or macrophages. This investigation seek to summarize current knowledge on the clinical impact on ARE of IL-6 -174G/C polymorphisms. Relevant published data was retrieved through Medline pertaining to kidney transplant outcome and IL-6 polymorphisms. Odds ratios (OR) with 95 % confidence intervals (CI) were used to assess the strength of the association. Z test was used to determine the significance of the pooled OR. Statistical heterogeneity was measured using the Q statistic. The effect of heterogeneity was quantified using the I 2 -statistic. A total of 16 studies, including 672 ARE transplanted cases and 1290 transplanted controls without rejection episodes, were collected in this meta-analysis. For high vs. low IL-6 genotypes, no heterogeneity (Q = 12.07, p = 0.67, I 2 = 0.0%) was observed among individual estimates, and original data was combined using the fixed-effects model. For the total population, we found no association between G/G and G/C IL-6 genotypes with ARE, we obtained an effect summary OR = 1.14, with a 95 % CI = 0.84-1.55, and p = 0.4. In conclusion, in recipients with a high producer (G/G and G/C) genotype of IL-6, the -174G/C polymorphism is not associated with acute rejection of renal allograft.
